查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2095042

大鼠和小鼠模型市場—2026-2032年全球市場預測

Rat & Mouse Model Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，大鼠和小鼠模型市場將成長至 47.4 億美元，複合年成長率為 8.89%。

主要市場統計數據
基準年 2025 26.1億美元
預計年份：2026年 27.8億美元
預測年份 2032 47.4億美元
複合年成長率 (%) 8.89%

大鼠和小鼠模型執行摘要

大鼠和小鼠模型仍然是生物醫學研究的基石，由於其遺傳學、生理學、繁殖效率和已充分闡明的疾病通路，使得在腫瘤學、免疫學、神經科學、代謝性疾病、感染疾病、傳染病、毒理學和藥理學等領域開展可重複的研究成為可能。大鼠和小鼠模型生態系統包括用於藥物發現、臨床前驗證、安全性檢驗和轉化研究的各種品系，例如近交系、非近交系、同合子、基因改造、基因敲除、基因敲入、條件性、人源化、無菌、無菌、免疫力缺乏和疾病特異性品系。對模型的需求源於持續不斷的需要，例如闡明複雜的生物機制、評估候選藥物以及產生監管申報所需的證據，同時還要遵循「3R原則」（替代、減少、改進）。推動該領域應用的關鍵因素包括CRISPR基因組編輯、先進的表現型分析、微生物組控制模型、患者來源的異質骨移植研究、人類免疫系統重建，以及日益普及的數位監測技術，這些技術能夠減輕動物壓力並提高數據品質。同時，倫理審查、可重複性預期、動物福利標準、病原體監測、供應鏈韌性以及在科學合理的範圍內整合非動物實驗方法等因素也日益影響著該領域的發展。隨著生物醫學研發流程變得更加精準和數據密集，大鼠和小鼠模型正從標準化的研究工具演變為連接基因組學、環境、表現型和治療反應的複雜生物學平台。

大鼠和小鼠模型領域的變革性變化

在鼠類模型領域，研究結構正從傳統的基於品系的實驗轉向精準、與人類相關且高度可控的實驗系統。基於CRISPR的基因組編輯技術正在加速標靶基因模型的構建，以及敲除、敲入、條件性等位基因和臨床相關突變模型的開發。人源化小鼠模型正在拓展免疫腫瘤學、感染疾病、發炎、移植和生物製藥等領域的研究能力。同時，由於體型和生理相容性，大鼠在神經科學、心血管研究、行為學、毒理學和外科手術模型中重新獲得重視。研究機構也更加重視微生物組標準化、無菌和無菌設施、環境控制和遺傳品質保證，以解決臨床前研究整體普遍存在的可重複性問題。數位化動物房系統、自動化籠具監控、遙測、影像和非侵入性生物標記正在改變終點資料的收集方式，實現縱向資料收集並減少動物操作次數。監管機構和資助機構日益要求報告透明、統計設計合理、將性別作為生物學變數加以考慮，並採用以健康為中心的方案。這些變化正在重塑採購和研究設計決策，因此，對能夠支援檢驗模型、明確定義的健康狀況、可靠的元資料和轉化相關性的綜合表現型分析服務的需求也日益成長。

人工智慧對大鼠和小鼠模型的累積影響

人工智慧正透過改進研究設計、動物福利監測、影像分析、表現型分析、群體管理和轉化解讀，對大鼠和小鼠模型生態系統產生日益顯著的影響。機器學習工具可以分析行為影片、步態模式、睡眠週期、腫瘤生長影像、組織病理切片和生理遙測數據，從而檢測到人工觀察可能遺漏的細微表現型​​。人工智慧驅動的實驗設計能夠提高統計功效的計算精度，減少不必要的動物使用，並有助於識別混雜變量，例如籠養效應、性別差異、微生物組變異性和晝夜節律。在動物飼養管理中，預測分析支持育種最佳化、基因分型規劃、健康監測和資源分配，有助於減少動物過剩並提高群體效率。在藥物發現和安全性研究中，人工智慧能夠整合體學數據、影像、病理學和動態測量數據，從而增強跨物種轉化研究，並允許在臨床前研究中更早地識別訊號。然而，人工智慧的引入也帶來了一些關鍵要求，例如經過驗證的演算法、檢驗的輸出結果、標準化的數據標註、偏差控制以及遵守動物研究管治。其累積影響並非在短期內取代大鼠和小鼠模型，而是透過改進資料提取、減少實驗重複、提高動物福利和增強實驗可重複性來最佳化現有模型的使用。

全球大鼠和小鼠模型研究的關鍵區域性見解

在亞太地區，大鼠和小鼠模型研究的成長得益於不斷擴大的生物醫學基礎設施、國家級生物技術計畫、日益活躍的轉化研究活動以及中國、印度、日本、韓國、澳洲和東南亞國協國家的大力學術投入。中國已成為基因組編輯、腫瘤模型、人源化模型和臨床前藥物研發領域的領先中心。同時，日本和韓國正致力於高品質疾病模型、再生醫學、神經科學和生技藥品的研究。印度憑藉大規模的科學研究人才儲備和日益完善的監管體系，正在加強其在合約研究、毒理學、疫苗和藥理學方面的能力。澳洲在動物倫理、免疫學、感染疾病和轉化醫學領域做出了卓越貢獻。北美地區在大鼠和小鼠模型創新方面仍處於領先地位，這得益於其雄厚的生物醫學研究資金、成熟的動物飼養基礎設施、健全的法規結構以及在基因修飾、免疫力缺乏和人源化囓齒動物模型方面的深厚專業知識。美國在癌症生物學、神經退化性疾病、罕見疾病、感染疾病和藥物安全領域擁有特別強大的影響力，而加拿大則以其學術研究網路、幹細胞科學和倫理監管而享有盛譽。拉丁美洲在藥理學、感染疾病、代謝性疾病和毒理學領域的能力正在發展，巴西和墨西哥是重要的研究中心，但基礎設施差異和資金籌措週期正在影響實施進程。歐洲的特點是嚴格的動物福利法規、對「3R」原則的全面實施以及在免疫學、神經科學、腫瘤學和毒理學領域的先進研究，德國、法國、英國、義大利、西班牙和其他歐洲領先的研究國家做出了重大貢獻。在中東，對生物醫學研究能力、基因組學和生命科學基礎設施的投資正在增加，尤其是在海灣國家。同時，在非洲，生物醫學和感染疾病研究能力正在逐步擴展，為區域衛生優先事項、人力資源發展、倫理管治和國際研究合作創造了機會。

影響大鼠和小鼠模型採用的關鍵群體見解

在東南亞國協，隨著生命科學投資的增加，大鼠和小鼠模型研究的重要性日益凸顯，這主要得益於區域內對熱帶疾病、代謝紊亂和藥物研發的關注。同時，生物醫學大學、疫苗研究、感染疾病控制計畫和臨床前服務基礎設施也在不斷發展。海灣合作理事會（GCC）正透過投資國家衛生研究策略、基因組學舉措、學術醫療中心和實驗室基礎設施來加強其作用，其中大鼠和小鼠模型支持糖尿病、心血管疾病、腫瘤學和精準醫學等領域的研究，以應對該地區的疾病負擔。歐盟為動物研究提供了最完善的管治環境之一，其統一的動物福利法、強制性的倫理審查以及強力的3R（替代、減少、改進）原則的實施，對成員國的研究設計、報告和模型選擇都產生了影響。金磚國家在鼠類模型研究領域構成了一個多元化且極具影響力的群體，匯集了中國大規模的模型開發和臨床前研究能力、印度不斷壯大的藥理學和毒理學基礎、巴西在感染疾病和代謝性疾病研究方面的優勢、俄羅斯的生物醫學傳統以及南非在社區衛生研究領域的貢獻。七國集團（G7）透過先進的生物醫學研究資助體系、嚴格的監管要求、複雜疾病模型的開發以及轉化科學領域豐富的學術出版物，持續引領全球最佳實踐。北約成員國，特別是那些擁有成熟的生命科學、國防和衛生研究計畫的國家，在毒理學、生物防禦、感染疾病、創傷、神經科學以及醫療對策研發等領域廣泛應用鼠類模型。這些群體共同關注的關鍵主題包括品質保證、遵守倫理標準、基因定義的模型、資料互通性以及數位化和計算工具整合的進步。

主要國家在大鼠和小鼠模型研究的趨勢

美國憑藉其完善的生物醫學研究基礎設施、積極利用基因改造模型以及在腫瘤學、免疫學、神經科學、罕見疾病和毒理學等領域的先進應用，在鼠類模型創新方面處於領先地位。加拿大則透過高品質的學術研究、幹細胞生物學、神經生物學、感染疾病研究以及健全的倫理監管來做出貢獻。墨西哥正在拓展其生物醫學和藥理學研究能力，囓齒動物模型為毒理學、代謝性疾病和感染疾病研究提供支持。巴西是拉丁美洲的主要貢獻者，利用鼠類模型進行免疫學、寄生蟲學、疫苗研究、代謝性疾病和藥理評估。英國因其在動物福利、神經科學、癌症研究、遺傳學和臨床前轉化方法方面的卓越管治而備受推崇，而德國則在分子生物學、免疫學、心血管研究、毒理學和高級表現型分析方面擁有深厚的專業知識。法國在領先的公共研究機構和嚴格的倫理審查支持下，正大力推廣囓齒動物模型在腫瘤學、感染疾病、神經科學和免疫學等廣泛領域的應用。俄羅斯在生物醫學、藥理學、生理學和實驗醫學領域擁有雄厚的實力，但國際合作研究的趨勢和採購情況可能會影響其研究方向。義大利和西班牙在腫瘤學、神經科學、發炎、代謝性疾病和藥理學領域十分活躍，並採用歐洲標準規範動物的使用和報告。中國在生物技術和轉化醫學領域的大規模投資支持下，是基因編輯小鼠和大鼠模型、人源化模型、免疫力缺乏模型以及疾病特異性小鼠和大鼠模型領域最具活力的國家之一。印度在其不斷發展的製藥和學術生態系統的推動下，正不斷鞏固其在毒理學、藥理學、疫苗研究和疾病建模方面的地位。日本長期以來在遺傳學、老化、神經科學、免疫學、再生醫學和高品質模型開發方面擁有強大的實力。澳洲在免疫學、感染疾病、癌症和動物倫理研究領域佔據領先地位，而韓國則在基因組編輯、腫瘤學、神經科學、再生醫學和臨床前研究基礎設施等領域迅速發展。這些國家共同展現了監管標準、資金優先事項、疾病負擔、技術能力和動物福利期望如何影響大鼠和小鼠模型的使用。

為大鼠和小鼠模型行業的領導者提供的實用建議

產業領導者應優先考慮科學合理的模型選擇，確保每種大鼠或小鼠模型均與研究的生物機制、治療方法、終點要求和轉化目標相符。各機構應透過實施基因鑑定、病原體監測、微生物組記錄、標準化飼養環境、在適當情況下採用性別平衡的研究設計以及按照公認的臨床前研究指南進行透明報告，來提高研究的可重複性。投資先進的模型平台，包括 CRISPR 編輯品系、人源化免疫系統模型、患者來源的異質骨移植、無菌系統和縱向表現型分析技術，可以提高數據的相關性，同時支持更有效率的研究。領導者應整合人工智慧驅動的分析、自動化行為評估、數位病理學、遙測和成像技術，以收集更豐富的資料集並減少主觀評估。動物福利仍然是重中之重，應透過積極採用 3R 原則、最佳化終點、非侵入性監測、環境豐富化和方案層面的審查來最大限度地減少動物的痛苦。應透過採購管道多元化、冷凍保存策略、緊急繁殖計劃以及清晰的健康狀況記錄來增強供應鏈韌性。最後，決策者應組成跨職能團隊，將獸醫、遺傳學家、生物資訊學家、藥理學家、統計學家和監管專家聯繫起來，以提高實驗的有效性，並加快將臨床前研究結果應用於臨床開發。

大鼠和小鼠模型分析的調查方法

本執行摘要採用系統化的二手研究途徑編寫，優先考慮檢驗、公開且科學可靠的資訊。調查方法包括對同行評審文獻、監管指南、動物福利框架、臨床前研究報告標準、生物醫學研究出版物、政府和機構資源以及與大鼠和小鼠模型開發和使用相關的科學共識文件的審查。分析檢視了關鍵模型類別，包括近交系和非近交系、基因修飾模型、免疫力缺乏模型、人源化模型、疾病特異性模型、無菌和已知菌叢系統以及毒理學模型。從可觀察的生物醫學研究活動、法規環境、科學基礎設施、資金優先事項、倫理管治以及生命科學生態系統的成熟度等方面，整合了區域、群體和國家層面的具體見解。這種研究方法避免了未經證實的數字聲明、市場規模估算、市場佔有率說明和預測。該報告重點關注已驗證的趨勢，包括基因組編輯技術的引入、3R原則的實施、可重複性要求、數位表現型分析、人工智慧驅動的分析以及轉化模型的改進。檢驗透過多方面的檢驗進行三角驗證，以確保其相關性、一致性以及對生物醫學研究、臨床前開發、實驗動物科學和轉化醫學領域相關人員的可操作價值。

結論

儘管大鼠和小鼠模型在生物醫學研究和臨床前開發中仍然發揮著至關重要的作用，但其設計、管理、分析和管治方法正在迅速發展。該領域正朝著更精準的基因工程、更高的人類相關性、更完善的環境和微生物組管理、更嚴格的倫理監管以及更強大的數位化表現型分析方向發展。人工智慧透過實現更客觀的數據解讀、最佳化育種、改善福利監測和更有效率的實驗設計，正在推動這項發展。各區域的優勢各不相同：北美和歐洲專注於先進的基礎設施和管治；亞太地區加速模型開發和轉化研究；拉丁美洲構建區域性疾病控制能力；中東和非洲則透過有針對性的投資和合作來擴展生物醫學能力。對於行業領導者而言，成功的關鍵在於將高品質的模型與嚴謹的研究設計、透明的報告、卓越的動物福利和數據驅動的決策相結合。隨著類器官、晶片器官系統和計算模型等非動物實驗方法的進步，大鼠和小鼠模型將擴大應用於綜合證據框架中，而不是孤立地使用。大鼠和小鼠模型的未來將取決於它們的科學有效性、倫理責任、可重複性以及產生轉化見解的能力，以支持更安全、更有效的療法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 大鼠和小鼠模型市場：按類型分類

  • 大鼠模型
    • 非近交系大鼠模型
    • 近交系大鼠模型
    • 基因改造大鼠模型
    • 免疫力缺乏大鼠模型
  • 小鼠模型
    • 口無遮攔模型
    • 近交系小鼠模型
    • 基因改造小鼠模型
      • 擊倒小鼠模型
      • 基因轉殖小鼠模型
      • 人源化小鼠模型
    • 免疫力缺乏小鼠模型
      • 裸鼠模型
      • SCID小鼠模型
      • NOG/NSG小鼠模型

第8章：大鼠與小鼠模型市場：依模型類型分類

  • 近交系模型
  • 非近交系模型
  • 基因改造模型
    • 淘汰賽模特兒
      • 建設性淘汰模型
      • 條件性敲除模型
      • 歸納敲除模型
    • 基因改造模型
    • 人形模型
    • 敲入式模型
  • 異種移植模型
    • 細胞株衍生的異種移植模型
    • 患者來源的異種移植模型
  • 類似車型
  • 化學誘導模型
  • 餵食誘導模型
  • 手術誘導模型
  • 自發性疾病模型
  • 記者模型

第9章：大鼠和小鼠模型市場：按服務類型分類

  • 供應標準型號
    • 活體動物
    • 冷凍保存的胚胎和精子
  • 自訂模型創建
    • 基因編輯的設計與構建
    • 胚胎學和顯微注射服務
    • 驗證和品管
  • 繁殖和群體管理
    • 制定育種策略
    • 殖民地擴張與維護
    • 健康監測
  • 冷凍保存與復甦
    • 精子冷凍保存
    • 胚胎冷凍保存
    • 復甦服務
  • 重新入伍並改善健康狀況
  • 表現型分析和行為測試
    • 生理表現型分析
    • 行為和認知測試
  • 體內測試服務
    • 功效測試
    • 疾病誘發和監測
    • 外科建模
  • 諮詢和監管支持

第10章：大鼠與小鼠模型市場：依應用分類

  • 藥物發現與篩檢
    • 目標識別與檢驗
    • 高通量篩檢
    • 先導藥物最適化
  • 臨床前療效試驗
    • 劑量反應研究
    • 聯合治療研究
  • 藥物動力學和動態
    • 吸收、分佈、代謝和排泄
    • 暴露-反應模型
  • 安全性和毒性測試
    • 急性毒性
    • 慢性毒性
    • 致癌性
    • 生殖和發育毒性
  • 疾病機轉與病理學研究
  • 生物標記的發現與檢驗
  • 轉化研究和仿生研究
  • 教育和培訓

第11章：大鼠和小鼠模型市場：按最終用戶分類

  • 製藥公司
    • 頂級跨國製藥公司
    • 中型和專業製藥公司
  • 生技公司
    • 一家歷史悠久的生物技術公司
    • 新興和虛擬生物技術公司
  • 受託研究機構
    • 世界 CRO
    • 小眾臨床前合約研究組織
  • 學術研究機構
    • 大學
    • 獨立研究機構
  • 政府和公共部門研究機構
  • 非營利組織和基金會
  • 產業聯盟和夥伴關係

第12章：大鼠和小鼠模型市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：大鼠與小鼠模型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：大鼠和小鼠模型市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Biocytogen Pharmaceuticals Co., Ltd.
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience International, Inc.
  • Cyagen Biosciences, Inc.
  • Envigo RMS, LLC
  • GemPharmatech Co., Ltd.
  • genOway SA
  • Harbour BioMed
  • Hera BioLabs, Inc.
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs SA
  • Oncodesign Precision Medicine
  • Oriental BioService Co., Ltd.
  • Ozgene Pty Ltd.
  • PerkinElmer, Inc.
  • Pharmatest Services Oy
  • PolyGene AG
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • TransCure bioServices
  • TransTech Pharma, Inc.
  • TransViragen, Inc.
  • Vivo Bio Tech Ltd.
Product Code: MRR-3A2E844FF329

The Rat & Mouse Model Market is projected to grow by USD 4.74 billion at a CAGR of 8.89% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.61 billion
Estimated Year [2026] USD 2.78 billion
Forecast Year [2032] USD 4.74 billion
CAGR (%) 8.89%

Rat & Mouse Model Executive Summary

Rat and mouse models remain foundational to biomedical research because their genetics, physiology, reproductive efficiency, and well-characterized disease pathways enable reproducible investigation across oncology, immunology, neuroscience, metabolic disorders, cardiovascular disease, infectious disease, toxicology, and pharmacology. The rat and mouse model ecosystem includes inbred, outbred, congenic, transgenic, knockout, knock-in, conditional, humanized, germ-free, gnotobiotic, immunodeficient, and disease-specific strains used in discovery research, preclinical validation, safety assessment, and translational studies. Demand is shaped by the continued need to understand complex biological mechanisms, evaluate therapeutic candidates, and generate evidence required for regulatory submissions while aligning with the 3Rs principles of replacement, reduction, and refinement. Key adoption drivers include CRISPR genome editing, advanced phenotyping, microbiome-controlled models, patient-derived xenograft research, human immune system reconstitution, and increasing use of digital monitoring to reduce stress and improve data quality. At the same time, the landscape is increasingly influenced by ethics review, reproducibility expectations, animal welfare standards, pathogen surveillance, supply-chain resilience, and the integration of non-animal methods where scientifically appropriate. As biomedical pipelines become more targeted and data-intensive, rat and mouse models are evolving from standardized research tools into precision biological platforms that connect genomics, environment, phenotype, and therapeutic response.

Transformative Shifts in the Rat & Mouse Model Landscape

The rat and mouse model landscape is undergoing a structural shift from conventional strain-based research toward precision, human-relevant, and highly controlled experimental systems. CRISPR-based genome editing has accelerated the creation of targeted genetic models, enabling faster development of knockouts, knock-ins, conditional alleles, and models carrying clinically relevant variants. Humanized mouse models are expanding the ability to study immune-oncology, infectious diseases, inflammation, transplantation, and biologics, while rats are gaining renewed importance in neuroscience, cardiovascular research, behavioral studies, toxicology, and surgical models because of their size and physiological suitability. Research organizations are also placing greater emphasis on microbiome standardization, germ-free and gnotobiotic facilities, environmental controls, and genetic quality assurance to address reproducibility concerns documented across preclinical science. Digital vivarium systems, automated home-cage monitoring, telemetry, imaging, and non-invasive biomarkers are transforming endpoint collection by enabling longitudinal data capture and reducing animal handling. Regulatory and funding bodies increasingly expect transparent reporting, appropriate statistical design, consideration of sex as a biological variable, and welfare-focused protocols. These shifts are reshaping procurement and study design decisions, with greater preference for validated models, defined health status, robust metadata, and integrated phenotyping services that support translational relevance.

Cumulative Impact of Artificial Intelligence on Rat & Mouse Models

Artificial intelligence is increasingly influencing the rat and mouse model ecosystem by improving study design, animal welfare monitoring, image analysis, phenotyping, colony management, and translational interpretation. Machine learning tools can analyze behavioral videos, gait patterns, sleep cycles, tumor growth images, histopathology slides, and physiological telemetry to detect subtle phenotypes that may be missed by manual observation. AI-supported experimental design can improve statistical power calculations, reduce unnecessary animal use, and help identify confounding variables such as cage effects, sex differences, microbiome variation, and circadian timing. In vivarium operations, predictive analytics supports breeding optimization, genotype planning, health surveillance, and resource allocation, helping reduce surplus animals and improve colony efficiency. In drug discovery and safety research, AI enables integration of omics data, imaging, pathology, and pharmacodynamic readouts to strengthen cross-species translation and identify signals earlier in the preclinical process. However, AI adoption also raises critical requirements for validated algorithms, explainable outputs, standardized data annotation, bias control, and compliance with animal research governance. The cumulative impact is not the replacement of rat and mouse models in the near term, but the refinement of their use through better data extraction, fewer experimental redundancies, improved welfare, and stronger reproducibility.

Key Regional Insights Across Global Rat & Mouse Model Research

In Asia-Pacific, growth in rat and mouse model research is supported by expanding biomedical infrastructure, national biotechnology programs, increasing translational research activity, and strong academic investment across China, India, Japan, South Korea, Australia, and ASEAN economies. China has become a major hub for genome editing, oncology models, humanized models, and preclinical drug development, while Japan and South Korea emphasize high-quality disease models, regenerative medicine, neuroscience, and biologics research. India is strengthening its contract research, toxicology, vaccine, and pharmacology capabilities, supported by a large scientific workforce and growing regulatory alignment. Australia contributes high standards in animal ethics, immunology, infectious disease, and translational medicine. North America remains one of the most advanced regions for rat and mouse model innovation, driven by extensive biomedical funding, mature vivarium infrastructure, strong regulatory frameworks, and deep expertise in genetically engineered, immunodeficient, and humanized rodent models. The United States is especially influential in cancer biology, neurodegeneration, rare disease, infectious disease, and safety pharmacology, while Canada is recognized for academic research networks, stem cell science, and ethical oversight. Latin America is developing capabilities in pharmacology, infectious disease, metabolic disorders, and toxicology, with Brazil and Mexico serving as important research centers, although infrastructure variability and funding cycles influence adoption. Europe is characterized by rigorous animal welfare regulation, strong implementation of the 3Rs, and advanced research across immunology, neuroscience, oncology, and toxicology, with major contributions from Germany, France, the United Kingdom, Italy, Spain, and other European research economies. The Middle East is investing in biomedical research capacity, genomics, and life science infrastructure, particularly in Gulf economies, while Africa is gradually expanding biomedical and infectious disease research capabilities, with opportunities linked to regional health priorities, training, ethical governance, and international research collaboration.

Key Group Insights Shaping Rat & Mouse Model Adoption

ASEAN is increasingly relevant to rat and mouse model research through expanding biomedical universities, vaccine research, infectious disease programs, and preclinical service capacity in countries with growing life science investment, supported by regional interest in tropical disease, metabolic disorders, and pharmaceutical development. The GCC is strengthening its role through national health research strategies, genomics initiatives, academic medical centers, and investment in laboratory infrastructure, with rat and mouse models supporting diabetes, cardiovascular disease, oncology, and precision medicine studies aligned with regional disease burdens. The European Union provides one of the most structured governance environments for animal research, with harmonized animal welfare legislation, mandatory ethical review, and strong 3Rs implementation that influence study design, reporting, and model selection across member states. BRICS countries represent a diverse and influential grouping for rat and mouse model activity, combining China's large-scale model generation and preclinical research capacity, India's expanding pharmacology and toxicology base, Brazil's infectious disease and metabolic research strengths, Russia's biomedical science legacy, and South Africa's role in regional health research. G7 countries continue to shape global best practices through advanced biomedical funding systems, stringent regulatory expectations, sophisticated disease model development, and strong publication output in translational science. NATO member countries, particularly those with established life science and defense-health research programs, use rat and mouse models in areas such as toxicology, biodefense, infectious disease, trauma, neuroscience, and medical countermeasure development. Across these groups, the defining themes are quality assurance, ethical compliance, genetically defined models, interoperable data, and increasing integration of digital and computational tools.

Key Country Insights for Rat & Mouse Model Research

The United States leads rat and mouse model innovation through extensive biomedical research infrastructure, strong use of genetically engineered models, and advanced applications in oncology, immunology, neuroscience, rare diseases, and toxicology. Canada contributes through high-quality academic research, stem cell biology, neurobiology, infectious disease studies, and robust ethics oversight. Mexico is expanding biomedical and pharmacology research capacity, with rodent models supporting toxicology, metabolic disease, and infectious disease studies. Brazil is a major Latin American contributor, using rat and mouse models in immunology, parasitology, vaccine research, metabolic disorders, and pharmacological evaluation. The United Kingdom is recognized for strong animal welfare governance, neuroscience, cancer research, genetics, and preclinical translational methods, while Germany has deep capabilities in molecular biology, immunology, cardiovascular research, toxicology, and advanced phenotyping. France supports broad rodent model use across oncology, infectious disease, neuroscience, and immunology, aided by major public research institutions and strict ethical review. Russia maintains expertise in biomedical science, pharmacology, physiology, and experimental medicine, although international collaboration dynamics and procurement conditions can affect research flow. Italy and Spain are active in oncology, neuroscience, inflammation, metabolic disease, and pharmacology, with European standards shaping animal use and reporting. China is one of the most dynamic countries for genome-edited, humanized, immunodeficient, and disease-specific mouse and rat models, supported by major investment in biotechnology and translational medicine. India is strengthening its position in toxicology, pharmacology, vaccine research, and disease modeling, driven by its expanding pharmaceutical and academic ecosystem. Japan has long-standing strengths in genetics, aging, neuroscience, immunology, regenerative medicine, and high-quality model development. Australia is prominent in immunology, infectious disease, cancer, and ethical animal research frameworks, while South Korea is advancing rapidly in genome editing, oncology, neuroscience, regenerative medicine, and preclinical research infrastructure. Collectively, these countries illustrate how regulatory standards, funding priorities, disease burden, technical capabilities, and animal welfare expectations shape rat and mouse model utilization.

Actionable Recommendations for Rat & Mouse Model Industry Leaders

Industry leaders should prioritize scientifically justified model selection, ensuring that each rat or mouse model is aligned with the biological mechanism, therapeutic modality, endpoint requirements, and translational objective of the study. Organizations should strengthen reproducibility by implementing genetic authentication, pathogen monitoring, microbiome documentation, standardized housing conditions, sex-balanced study designs where appropriate, and transparent reporting aligned with accepted preclinical research guidelines. Investment in advanced model platforms, including CRISPR-engineered strains, humanized immune system models, patient-derived xenografts, gnotobiotic systems, and longitudinal phenotyping technologies, can improve data relevance while supporting more efficient study execution. Leaders should integrate AI-enabled analytics, automated behavioral assessment, digital pathology, telemetry, and imaging to capture richer datasets and reduce subjective scoring. Animal welfare must remain central, with active adoption of the 3Rs, refined endpoints, non-invasive monitoring, environmental enrichment, and protocol-level review to minimize distress. Supply-chain resilience should be improved through diversified sourcing, cryopreservation strategies, contingency breeding plans, and clear health-status documentation. Finally, decision-makers should build cross-functional teams that connect veterinarians, geneticists, bioinformaticians, pharmacologists, statisticians, and regulatory specialists to improve experimental validity and accelerate translation from preclinical findings to clinical development.

Research Methodology for Rat & Mouse Model Analysis

This executive summary is developed through a structured secondary research approach that prioritizes verified, publicly available, and scientifically credible information. The methodology includes review of peer-reviewed literature, regulatory guidance, animal welfare frameworks, preclinical research reporting standards, biomedical research publications, government and institutional resources, and scientific consensus documents related to rat and mouse model development and use. The analysis considers major model categories, including inbred and outbred strains, genetically engineered models, immunodeficient models, humanized models, disease-specific models, germ-free and gnotobiotic systems, and toxicology models. Regional, group, and country insights are synthesized from observable biomedical research activity, regulatory environments, scientific infrastructure, funding priorities, ethical governance, and life science ecosystem maturity. The research approach avoids unsupported numerical claims, market sizing, market share statements, and forecasting. Emphasis is placed on validated trends such as genome editing adoption, 3Rs implementation, reproducibility requirements, digital phenotyping, AI-enabled analysis, and translational model refinement. Findings are triangulated across multiple categories of evidence to ensure relevance, consistency, and practical value for stakeholders involved in biomedical research, preclinical development, laboratory animal science, and translational medicine.

Conclusion

Rat and mouse models continue to play a critical role in biomedical discovery and preclinical development, while the way they are designed, managed, analyzed, and governed is changing rapidly. The sector is moving toward more precise genetic engineering, improved human relevance, better environmental and microbiome control, stronger ethical oversight, and richer digital phenotyping. Artificial intelligence is reinforcing this evolution by enabling more objective data interpretation, optimized breeding, improved welfare surveillance, and more efficient experimental design. Regional strengths vary, with North America and Europe emphasizing advanced infrastructure and governance, Asia-Pacific accelerating model generation and translational research, Latin America building capacity around regional disease priorities, and the Middle East and Africa expanding biomedical capabilities through targeted investment and collaboration. For industry leaders, success depends on combining high-quality models with rigorous study design, transparent reporting, animal welfare excellence, and data-driven decision-making. As non-animal methods, organoids, organ-on-chip systems, and computational models advance, rat and mouse models will increasingly be used in integrated evidence frameworks rather than in isolation. The future of the rat and mouse model landscape will be defined by scientific validity, ethical responsibility, reproducibility, and the ability to generate translational insights that support safer and more effective therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Rat & Mouse Model Market, by Species

  • 7.1. Introduction
  • 7.2. Rat Models
    • 7.2.1. Outbred Rat Models
    • 7.2.2. Inbred Rat Models
    • 7.2.3. Genetically Engineered Rat Models
    • 7.2.4. Immunodeficient Rat Models
  • 7.3. Mouse Models
    • 7.3.1. Outbred Mouse Models
    • 7.3.2. Inbred Mouse Models
    • 7.3.3. Genetically Engineered Mouse Models
      • 7.3.3.1. Knockout Mouse Models
      • 7.3.3.2. Transgenic Mouse Models
      • 7.3.3.3. Humanized Mouse Models
    • 7.3.4. Immunodeficient Mouse Models
      • 7.3.4.1. Nude Mouse Models
      • 7.3.4.2. SCID Mouse Models
      • 7.3.4.3. NOG/NSG Mouse Models

8. Rat & Mouse Model Market, by Model Type

  • 8.1. Introduction
  • 8.2. Inbred Models
  • 8.3. Outbred Models
  • 8.4. Genetically Engineered Models
    • 8.4.1. Knockout Models
      • 8.4.1.1. Constitutive Knockout Models
      • 8.4.1.2. Conditional Knockout Models
      • 8.4.1.3. Inducible Knockout Models
    • 8.4.2. Transgenic Models
    • 8.4.3. Humanized Models
    • 8.4.4. Knock-in Models
  • 8.5. Xenograft Models
    • 8.5.1. Cell Line-Derived Xenograft Models
    • 8.5.2. Patient-Derived Xenograft Models
  • 8.6. Syngeneic Models
  • 8.7. Chemically Induced Models
  • 8.8. Diet-Induced Models
  • 8.9. Surgically Induced Models
  • 8.10. Spontaneous Disease Models
  • 8.11. Reporter Models

9. Rat & Mouse Model Market, by Service Type

  • 9.1. Introduction
  • 9.2. Standard Model Supply
    • 9.2.1. Live Animals
    • 9.2.2. Cryopreserved Embryos & Sperm
  • 9.3. Custom Model Generation
    • 9.3.1. Gene Editing Design & Construction
    • 9.3.2. Embryology & Microinjection Services
    • 9.3.3. Validation & Quality Control
  • 9.4. Breeding & Colony Management
    • 9.4.1. Breeding Strategy Design
    • 9.4.2. Colony Expansion & Maintenance
    • 9.4.3. Health Monitoring
  • 9.5. Cryopreservation & Recovery
    • 9.5.1. Sperm Cryopreservation
    • 9.5.2. Embryo Cryopreservation
    • 9.5.3. Resuscitation Services
  • 9.6. Rederivation & Health Status Improvement
  • 9.7. Phenotyping & Behavior Testing
    • 9.7.1. Physiological Phenotyping
    • 9.7.2. Behavioral & Cognitive Testing
  • 9.8. In Vivo Study Services
    • 9.8.1. Efficacy Studies
    • 9.8.2. Disease Induction & Monitoring
    • 9.8.3. Surgical Modeling
  • 9.9. Consulting & Regulatory Support

10. Rat & Mouse Model Market, by Application

  • 10.1. Introduction
  • 10.2. Drug Discovery & Screening
    • 10.2.1. Target Identification & Validation
    • 10.2.2. High-Throughput Screening
    • 10.2.3. Lead Optimization
  • 10.3. Preclinical Efficacy Studies
    • 10.3.1. Dose-Response Studies
    • 10.3.2. Combination Therapy Studies
  • 10.4. Pharmacokinetics & Pharmacodynamics
    • 10.4.1. Absorption, Distribution, Metabolism & Excretion
    • 10.4.2. Exposure-Response Modeling
  • 10.5. Safety & Toxicology Testing
    • 10.5.1. Acute Toxicity
    • 10.5.2. Chronic Toxicity
    • 10.5.3. Carcinogenicity
    • 10.5.4. Reproductive & Developmental Toxicity
  • 10.6. Disease Mechanism & Pathophysiology Research
  • 10.7. Biomarker Discovery & Validation
  • 10.8. Translational & Biomimetic Studies
  • 10.9. Education & Training

11. Rat & Mouse Model Market, by End User

  • 11.1. Introduction
  • 11.2. Pharmaceutical Companies
    • 11.2.1. Top-Tier & Multinational Pharma
    • 11.2.2. Mid-Size & Specialty Pharma
  • 11.3. Biotechnology Companies
    • 11.3.1. Established Biotech Firms
    • 11.3.2. Emerging & Virtual Biotech
  • 11.4. Contract Research Organizations
    • 11.4.1. Global CROs
    • 11.4.2. Niche Preclinical CROs
  • 11.5. Academic & Research Institutes
    • 11.5.1. Universities
    • 11.5.2. Independent Research Institutes
  • 11.6. Government & Public Sector Laboratories
  • 11.7. Nonprofit & Foundations
  • 11.8. Industry Consortia & Partnerships

12. Rat & Mouse Model Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Rat & Mouse Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rat & Mouse Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Biocytogen Pharmaceuticals Co., Ltd.
  • 16.2. Champions Oncology, Inc.
  • 16.3. Charles River Laboratories International, Inc.
  • 16.4. Crown Bioscience International, Inc.
  • 16.5. Cyagen Biosciences, Inc.
  • 16.6. Envigo RMS, LLC
  • 16.7. GemPharmatech Co., Ltd.
  • 16.8. genOway S.A.
  • 16.9. Harbour BioMed
  • 16.10. Hera BioLabs, Inc.
  • 16.11. inGenious Targeting Laboratory, Inc.
  • 16.12. Janvier Labs SA
  • 16.13. Oncodesign Precision Medicine
  • 16.14. Oriental BioService Co., Ltd.
  • 16.15. Ozgene Pty Ltd.
  • 16.16. PerkinElmer, Inc.
  • 16.17. Pharmatest Services Oy
  • 16.18. PolyGene AG
  • 16.19. Taconic Biosciences, Inc.
  • 16.20. The Jackson Laboratory
  • 16.21. TransCure bioServices
  • 16.22. TransTech Pharma, Inc.
  • 16.23. TransViragen, Inc.
  • 16.24. Vivo Bio Tech Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RAT & MOUSE MODEL MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RAT & MOUSE MODEL MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RAT & MOUSE MODEL MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RAT & MOUSE MODEL MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RAT & MOUSE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RAT & MOUSE MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL RAT & MOUSE MODEL MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL RAT & MOUSE MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL RAT & MOUSE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OUTBRED RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OUTBRED RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OUTBRED RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INBRED RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INBRED RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INBRED RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENETICALLY ENGINEERED RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENETICALLY ENGINEERED RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENETICALLY ENGINEERED RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNODEFICIENT RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNODEFICIENT RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNODEFICIENT RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OUTBRED MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OUTBRED MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OUTBRED MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INBRED MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INBRED MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INBRED MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENETICALLY ENGINEERED MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENETICALLY ENGINEERED MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENETICALLY ENGINEERED MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL KNOCKOUT MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL KNOCKOUT MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL KNOCKOUT MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSGENIC MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSGENIC MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSGENIC MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMANIZED MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMANIZED MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMANIZED MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNODEFICIENT MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNODEFICIENT MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNODEFICIENT MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUDE MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUDE MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUDE MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SCID MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SCID MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SCID MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NOG/NSG MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NOG/NSG MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NOG/NSG MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INBRED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INBRED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INBRED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OUTBRED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OUTBRED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OUTBRED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENETICALLY ENGINEERED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENETICALLY ENGINEERED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENETICALLY ENGINEERED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL KNOCKOUT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL KNOCKOUT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL KNOCKOUT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONSTITUTIVE KNOCKOUT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CONSTITUTIVE KNOCKOUT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONSTITUTIVE KNOCKOUT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CONDITIONAL KNOCKOUT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONDITIONAL KNOCKOUT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONDITIONAL KNOCKOUT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INDUCIBLE KNOCKOUT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INDUCIBLE KNOCKOUT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INDUCIBLE KNOCKOUT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSGENIC MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSGENIC MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TRANSGENIC MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMANIZED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMANIZED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMANIZED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL KNOCK-IN MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL KNOCK-IN MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL KNOCK-IN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL XENOGRAFT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL XENOGRAFT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL XENOGRAFT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL LINE-DERIVED XENOGRAFT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL LINE-DERIVED XENOGRAFT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL LINE-DERIVED XENOGRAFT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PATIENT-DERIVED XENOGRAFT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PATIENT-DERIVED XENOGRAFT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PATIENT-DERIVED XENOGRAFT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SYNGENEIC MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYNGENEIC MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SYNGENEIC MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHEMICALLY INDUCED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CHEMICALLY INDUCED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHEMICALLY INDUCED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIET-INDUCED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIET-INDUCED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIET-INDUCED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SURGICALLY INDUCED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SURGICALLY INDUCED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SURGICALLY INDUCED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SPONTANEOUS DISEASE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SPONTANEOUS DISEASE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SPONTANEOUS DISEASE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL REPORTER MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL REPORTER MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL REPORTER MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL STANDARD MODEL SUPPLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL STANDARD MODEL SUPPLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL STANDARD MODEL SUPPLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL LIVE ANIMALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVE ANIMALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL LIVE ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CRYOPRESERVED EMBRYOS & SPERM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CRYOPRESERVED EMBRYOS & SPERM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CRYOPRESERVED EMBRYOS & SPERM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CUSTOM MODEL GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CUSTOM MODEL GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CUSTOM MODEL GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE EDITING DESIGN & CONSTRUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENE EDITING DESIGN & CONSTRUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE EDITING DESIGN & CONSTRUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL EMBRYOLOGY & MICROINJECTION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL EMBRYOLOGY & MICROINJECTION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EMBRYOLOGY & MICROINJECTION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VALIDATION & QUALITY CONTROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VALIDATION & QUALITY CONTROL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VALIDATION & QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BREEDING & COLONY MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREEDING & COLONY MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BREEDING & COLONY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREEDING STRATEGY DESIGN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BREEDING STRATEGY DESIGN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREEDING STRATEGY DESIGN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL COLONY EXPANSION & MAINTENANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL COLONY EXPANSION & MAINTENANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL COLONY EXPANSION & MAINTENANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEALTH MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HEALTH MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEALTH MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CRYOPRESERVATION & RECOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CRYOPRESERVATION & RECOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CRYOPRESERVATION & RECOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL SPERM CRYOPRESERVATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL SPERM CRYOPRESERVATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL SPERM CRYOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL EMBRYO CRYOPRESERVATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL EMBRYO CRYOPRESERVATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL EMBRYO CRYOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL RESUSCITATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL RESUSCITATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL RESUSCITATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL REDERIVATION & HEALTH STATUS IMPROVEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL REDERIVATION & HEALTH STATUS IMPROVEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL REDERIVATION & HEALTH STATUS IMPROVEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PHENOTYPING & BEHAVIOR TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL PHENOTYPING & BEHAVIOR TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PHENOTYPING & BEHAVIOR TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL PHYSIOLOGICAL PHENOTYPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL PHYSIOLOGICAL PHENOTYPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL PHYSIOLOGICAL PHENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BEHAVIORAL & COGNITIVE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BEHAVIORAL & COGNITIVE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BEHAVIORAL & COGNITIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL IN VIVO STUDY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL IN VIVO STUDY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL IN VIVO STUDY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL EFFICACY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL EFFICACY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL EFFICACY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL DISEASE INDUCTION & MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL DISEASE INDUCTION & MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL DISEASE INDUCTION & MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL SURGICAL MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL SURGICAL MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL SURGICAL MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CONSULTING & REGULATORY SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CONSULTING & REGULATORY SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CONSULTING & REGULATORY SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL DRUG DISCOVERY & SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG DISCOVERY & SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL DRUG DISCOVERY & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL HIGH-THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL HIGH-THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL HIGH-THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL PRECLINICAL EFFICACY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL PRECLINICAL EFFICACY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL PRECLINICAL EFFICACY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL DOSE-RESPONSE STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL DOSE-RESPONSE STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL DOSE-RESPONSE STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL COMBINATION THERAPY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL COMBINATION THERAPY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL COMBINATION THERAPY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL PHARMACOKINETICS & PHARMACODYNAMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL PHARMACOKINETICS & PHARMACODYNAMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL PHARMACOKINETICS & PHARMACODYNAMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL ABSORPTION, DISTRIBUTION, METABOLISM & EXCRETION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL ABSORPTION, DISTRIBUTION, METABOLISM & EXCRETION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL ABSORPTION, DISTRIBUTION, METABOLISM & EXCRETION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL EXPOSURE-RESPONSE MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL EXPOSURE-RESPONSE MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL EXPOSURE-RESPONSE MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL SAFETY & TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL SAFETY & TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL SAFETY & TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL ACUTE TOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL ACUTE TOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ACUTE TOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL CHRONIC TOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL CHRONIC TOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CHRONIC TOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL CARCINOGENICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL CARCINOGENICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL CARCINOGENICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL REPRODUCTIVE & DEVELOPMENTAL TOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL REPRODUCTIVE & DEVELOPMENTAL TOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL REPRODUCTIVE & DEVELOPMENTAL TOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL DISEASE MECHANISM & PATHOPHYSIOLOGY RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL DISEASE MECHANISM & PATHOPHYSIOLOGY RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL DISEASE MECHANISM & PATHOPHYSIOLOGY RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL BIOMARKER DISCOVERY & VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOMARKER DISCOVERY & VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL BIOMARKER DISCOVERY & VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL TRANSLATIONAL & BIOMIMETIC STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL TRANSLATIONAL & BIOMIMETIC STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL TRANSLATIONAL & BIOMIMETIC STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL TOP-TIER & MULTINATIONAL PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL TOP-TIER & MULTINATIONAL PHARMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL TOP-TIER & MULTINATIONAL PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL MID-SIZE & SPECIALTY PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL MID-SIZE & SPECIALTY PHARMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL MID-SIZE & SPECIALTY PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL ESTABLISHED BIOTECH FIRMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL ESTABLISHED BIOTECH FIRMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL ESTABLISHED BIOTECH FIRMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL EMERGING & VIRTUAL BIOTECH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL EMERGING & VIRTUAL BIOTECH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL EMERGING & VIRTUAL BIOTECH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL GLOBAL CROS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL GLOBAL CROS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL GLOBAL CROS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL NICHE PRECLINICAL CROS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL NICHE PRECLINICAL CROS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL NICHE PRECLINICAL CROS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL UNIVERSITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL UNIVERSITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL UNIVERSITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL INDEPENDENT RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL INDEPENDENT RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL INDEPENDENT RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL GOVERNMENT & PUBLIC SECTOR LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL GOVERNMENT & PUBLIC SECTOR LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL GOVERNMENT & PUBLIC SECTOR LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL NONPROFIT & FOUNDATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL NONPROFIT & FOUNDATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL NONPROFIT & FOUNDATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL INDUSTRY CONSORTIA & PARTNERSHIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL INDUSTRY CONSORTIA & PARTNERSHIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. GLOBAL INDUSTRY CONSORTIA & PARTNERSHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY XENOGRAFT MODELS, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY STANDARD MODEL SUPPLY, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY CUSTOM MODEL GENERATION, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY BREEDING & COLONY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVATION & RECOVERY, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY PHENOTYPING & BEHAVIOR TESTING, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY IN VIVO STUDY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY DRUG DISCOVERY & SCREENING, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY PRECLINICAL EFFICACY STUDIES, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY PHARMACOKINETICS & PHARMACODYNAMICS, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY SAFETY & TOXICOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 316. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 318. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 320. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, 2018-2032 (USD MILLION)
  • TABLE 324. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY XENOGRAFT MODELS, 2018-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY STANDARD MODEL SUPPLY, 2018-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY CUSTOM MODEL GENERATION, 2018-2032 (USD MILLION)
  • TABLE 328. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY BREEDING & COLONY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVATION & RECOVERY, 2018-2032 (USD MILLION)
  • TABLE 330. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY PHENOTYPING & BEHAVIOR TESTING, 2018-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY IN VIVO STUDY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 332. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY DRUG DISCOVERY & SCREENING, 2018-2032 (USD MILLION)
  • TABLE 334. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY PRECLINICAL EFFICACY STUDIES, 2018-2032 (USD MILLION)
  • TABLE 335. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY PHARMACOKINETICS & PHARMACODYNAMICS, 2018-2032 (USD MILLION)
  • TABLE 336. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY SAFETY & TOXICOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 337. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 339. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 340. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 341. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 342. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 343. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 344. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 345. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 346. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 347. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 348. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 350. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, 2018-2032 (USD MILLION)
  • TABLE 351. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY XEN